These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Toward an oligonucleotide therapy for Duchenne muscular dystrophy: a complex development challenge. Wood MJ Sci Transl Med; 2010 Mar; 2(25):25ps15. PubMed ID: 20424011 [TBL] [Abstract][Full Text] [Related]
47. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Béroud C; Tuffery-Giraud S; Matsuo M; Hamroun D; Humbertclaude V; Monnier N; Moizard MP; Voelckel MA; Calemard LM; Boisseau P; Blayau M; Philippe C; Cossée M; Pagès M; Rivier F; Danos O; Garcia L; Claustres M Hum Mutat; 2007 Feb; 28(2):196-202. PubMed ID: 17041910 [TBL] [Abstract][Full Text] [Related]
48. Development of therapy for Duchenne muscular dystrophy. Zhang S; Xie H; Zhou G; Yang Z Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2007 Feb; 21(2):194-203. PubMed ID: 17357471 [TBL] [Abstract][Full Text] [Related]
49. Moving towards successful exon-skipping therapy for Duchenne muscular dystrophy. Nakamura A J Hum Genet; 2017 Oct; 62(10):871-876. PubMed ID: 28566768 [TBL] [Abstract][Full Text] [Related]
50. Non-viral gene therapy for Duchenne muscular dystrophy: progress and challenges. Rando TA Biochim Biophys Acta; 2007 Feb; 1772(2):263-71. PubMed ID: 17005381 [TBL] [Abstract][Full Text] [Related]